Biotech entity
Every one of those 1 sits in a single category, pharma. C-Further is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Coya Therapeutics appears in 1 tracked Biotech story from March 15, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 15, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. C-Further is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Coya Therapeutics appears in 1 tracked Biotech story from March 15, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Coya Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Coya Therapeutics and MiNK Therapeutics are scheduled to report quarterly financial results this Tuesday, with investors focused on cash runway and clinical progress. These updates come at a critical juncture for both companies as they advance novel cell therapies for neurodegeneration and oncology, respectively.
Coya Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
